**Core Concept**
Myocardial remodeling in congestive heart failure (CHF) involves changes in the heart's structure, including hypertrophy, fibrosis, and chamber dilation. Reducing these changes can improve symptoms and outcomes. Various pharmacological agents can mitigate myocardial remodeling.

**Why the Correct Answer is Right**
The goal of reducing myocardial remodeling is to preserve cardiac function and prevent progression of heart failure. Beta-blockers, ACE inhibitors, and ARBs (angiotensin receptor blockers) are commonly used for this purpose. They work by decreasing afterload, reducing preload, and inhibiting the renin-angiotensin-aldosterone system (RAAS), which is activated in heart failure. This system promotes vasoconstriction, sodium retention, and fluid overload, exacerbating cardiac remodeling.

**Why Each Wrong Option is Incorrect**
**Option A:** (Note: Option A is missing. Please provide the options for a complete explanation.)
**Option B:** (Note: Option B is missing. Please provide the options for a complete explanation.)
**Option C:** (Note: Option C is missing. Please provide the options for a complete explanation.)

**Clinical Pearl / High-Yield Fact**
In patients with CHF, initiation of beta-blockers or ACE inhibitors/ARBs should be done gradually to avoid exacerbating heart failure symptoms. This is because these agents can initially worsen heart failure by reducing contractility and increasing peripheral resistance.

**Correct Answer:** Not enough information to determine the correct answer. Please provide the options for a complete explanation.